3.Clinical observation on different acupuncture and moxibustion therapies for treatment of postsurgical gastroparesis syndrome.
Chinese Acupuncture & Moxibustion 2007;27(3):173-175
OBJECTIVETo optimize therapy of acupuncture and moxibustion for postsurgical gastroparesis syndrome (PGS).
METHODSForty-one cases of PGS were randomly divided into 3 groups in order of visiting. Group A (n = 17) were treated by warming needle moxibustion, group B (n = 12) by acupuncture plus auricular point sticking, and group C (n = 12) by routine acupuncture. Changes of gastric drainage volume, therapeutic times and cured rate were investigated in the 3 groups.
RESULTSAll the 3 therapeutic methods could significantly decrease gastric drainage volume. The cured rate was 100.0% and the therapeutic times was (7.24 +/- 3.87) in the group A, 66.7%, (9.83 +/- 4.60) times in the group B and 75.0%, (15.25 +/- 3.81) times in the group C, with significant differences in the cured rate and the therapeutic times among the 3 groups (P < 0.05, P < 0.01).
CONCLUSIONThe warming needle moxibustion is the best method for PGS, with less therapeutic times, high cured rate and rapid effect.
Acupuncture Points ; Acupuncture Therapy ; methods ; Adult ; Aged ; Female ; Gastroparesis ; therapy ; Humans ; Male ; Middle Aged ; Moxibustion ; methods ; Postoperative Complications ; therapy
4.Steroid-resistant nephrotic syndrome and NPHS1 gene.
Chinese Journal of Pediatrics 2011;49(11):862-865
5.Detection of Glu-plasminogen in the human plasma and its clinical significance
Dao LI ; Quan CHEN ; Hong WANG ; Jianxin LI ; Hongl WANG
Chinese Journal of Pathophysiology 1999;0(09):-
AIM: To observe the changes of plasma content of Glu-plasminogen (plasmin, Pln) in patients during blood coagulation and/or fibrinolytic system activation. METHODS: Using specific McAb to antigenic determinant in NH 2 terminal (1-65 aa) of Pln and specific McAb to antigenic determinant in heavy chain of plasminogen, the sandwiched ELISA method was established to detect Glu-plasminogen and total plasminogen in human plasma collected from 220 normal controls and 40 patients after heart surgery. RESULTS: The average total plasminogen was (231.8?62.1) mg/L and average Glu-plasminogen was (231.9?45.8) mg/L in 220 normal controls, the ratio of Glu-plasminogen to total plasminogen (G/P) was 0.91. The ratio of Glu-plasminogen [(152.4?68.1) mg/L] to total plasminogen [(268.9?73.3) mg/L] in 40 patients after heart surgery was significantly lower than that in normal controls ( P
6.The study on production of anti-thrombomodulin antibodies using genetic immunization
Gaochao QIAN ; Hong WANG ; Zuoya ZHENG ; Dao LI ; Hongli WANG
Chinese Journal of Laboratory Medicine 2001;0(04):-
Objective To produce anti-thrombomodulin antibodies.Methods Using genetic immunization: Eukaryotic expression plasmid pcDNA3.1/TM(LEO),encoding all the extracellular domain of human thrombomodulin and signal peptides but lacking the transmembrance and cytoplasmic domains was constructed, which recombinant thrombomodulin was secreted soluble product. The plasmid was isolated from large-scale bacterial cultures by treatment with alkali and SDS, purified by precipitation with polyethylene Glycol (PEG). Recombinant plasmid was injected into tibial muscle of BALB/c mice. The productions of TM and anti-TM have been detected. Results The positive of RT-PCR and expressed TM identified the function of the recombinant plasmid. The pcDNA3.1/TM(LEO) induced higher titer of anti-TM. The antibody titer peaked between the 5th and 7th injection with a titer of 1∶8 000 detected by cell-ELISA coated with EVC-304. Specificity has been identified by western blot and immunohistochemistry.Conclusion The production of antibody through genetic immunization was a feasible method due to the difficulties in obtaining and purification of natural thrombomodulin.
7. Evidence-based for venous thromboembolism prevention to Perioperative patients in Orthopedic
Ruting GU ; Kai ZHU ; Xia HUANG ; Fang WANG ; Yanqin CHENG ; Lili LYU ; Aiping ZHAO
Chinese Journal of Practical Nursing 2019;35(21):1632-1637
Objective:
To integrate the best evidence of venous thromboembolism (VTE) prevention into practice, improve nurses′ compliance, and reduce the incidence of VTE in orthopaedic department.
Methods:
Guided by the standard procedure in the JBI-Paces program, collected the best evidence from online databases and set the standards. Collected data through field observation, interviews and review of nursing records. A total of 167 patients and 36 nurses we recruited in the study and audited twice. We judged the result by the knowledge level of nurses and patients, nurses
8.Report of 24 cases with low back pain occurred after lumbar puncture.
Qing-min ZHANG ; Dao-bin WANG ; Lin SHI
Chinese Journal of Pediatrics 2003;41(4):305-306
Adolescent
;
Child
;
Child, Preschool
;
Female
;
Humans
;
Infant
;
Low Back Pain
;
etiology
;
Male
;
Spinal Puncture
;
adverse effects
10.Clinical report of intravitreal Bevacizumab for 26 cases with retinopathy of prematurity in Zone Ⅰ
Feng, CHEN ; Dao-Man, XIANG ; Jian-Xun, WANG ; Tian, LIU
International Eye Science 2016;16(7):1363-1365
AIM: To investigate the clinical effects of intravitreal Bevacizumab for 26 cases with retinopathy of prematurity (ROP) in Zone Ⅰ.
METHODS:A retrospective study. Totally 26 ROP infants between September 2013 and October 2014 diagnosed as high - risk ROP in Zone Ⅰ had been treated with intravitreal bevacizumab. They were divided into three groups, pre - threshold ROP, threshold ROP and acute posterior ROP ( APROP ). Postoperative effects were compared.
RESULTS:There were 26 infants (52 eyes) diagnosed as ROP in Zone Ⅰ, including 3 infants( 6 eyes) with pre -threshold ROP, 15 infants (30 eyes) with threshold ROP and 8 infants (16 eyes) with APROP. The first operation recovery rate of three groups respectively were 100% (6 /6), 60% ( 18 / 30 ) and 75% ( 12 / 16 ), which were not significantly different (P>0. 05).
CONCLUSION:Intravitreal bevacizumab for ROP in ZoneⅠ seems effective and has some advantages over conventional laser treatment, which could be first line treatment for high-risk ROP in Zone Ⅰ.